Extended Data Fig. 7: Decreased CSF Aβ1–42 and increased pTau levels in APOE4 carriers with cognitive impairment.
From: APOE4 leads to blood–brain barrier dysfunction predicting cognitive decline
a, CSF Aβ1–42 levels in individuals with CDR 0 bearing APOE3 (black, n = 141) or APOE4 (red, n = 83) and with CDR 0.5 bearing APOE3 (n = 39) or APOE4 (n = 41). b, CSF Aβ1–42 levels in APOE3 (n = 89) and APOE4 (n = 55) carriers with no cognitive domains impaired, APOE3 (n = 29) and APOE4 (n = 31) carriers with one cognitive domain impaired, and APOE3 (n = 17) and APOE4 (n = 14) carriers with two or more cognitive domains impaired. c, CSF Aβ1-42 levels (estimated marginal means ± s.e.m. from ANCOVA models corrected for age, sex, education, and CSF sPDGFRβ levels) in individuals with CDR 0 bearing APOE3 (n = 141) or APOE4 (n = 83) and with CDR 0.5 bearing APOE3 (n = 39) or APOE4 (n = 41). d, CSF pTau levels in individuals with CDR 0 bearing APOE3 (n = 141) or APOE4 (n = 82) and with CDR 0.5 bearing APOE3 (n = 39) or APOE4 (n = 43). e, CSF pTau levels in APOE3 (n = 89) and APOE4 (n = 56) carriers with no cognitive domains impaired, APOE3 (n = 29) and APOE4 (n = 30) carriers with one cognitive domain impaired, and APOE3 (n = 17) and APOE4 (n = 15) carriers with two or more cognitive domains impaired. f, CSF pTau levels (estimated marginal means ± s.e.m. from ANCOVA models corrected for age, sex, education, and CSF sPDGFRβ levels) in individuals with CDR 0 bearing APOE3 (n = 141) or APOE4 (red, n = 82) and with CDR 0.5 bearing APOE3 (n = 39) or APOE4 (n = 43). Violin plots: continuous lines, median; dotted lines, IQR. CSF Aβ1–42 and pTau values were log10-transformed before statistical analysis because they had a non-normal distribution. Significance tests from ANCOVAs for main effects and post hoc comparisons controlling for age, sex, and education.
